drugset / Trial / NCT04581629

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

NCT04581629

Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Timeline

Start
2020-09-20
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Encaleret Small molecule Oral